Clinical Trials Directory

Trials / Completed

CompletedNCT00299221

Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients

Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Newark Beth Israel Medical Center · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This was a study to compare less intense immunosuppression with a more traditional approach. The hypothesis was that less immunosuppression will provide similar protection against rejection than typical 2-3 drug therapy.

Detailed description

This was a prospective, randomized, controlled (open-label) trial of 2 different strategies of immunosuppression in de novo post-heart transplant patients. The hypothesis was that immunosuppression with tacrolimus and mycophenolate mofetil, coupled with rapid steroid weaning would provide similar anti-rejection efficacy as tacrolimus with only a 2 week course of mycophenolate mofetil but including the same rapid steroid wean. The primary endpoint was the mean International Society for Heart and Lung Transplantation (ISHLT) biopsy score over the first 6 months post-transplant. Secondary endpoints included the incidence of adverse events over the first year post-transplant, as well as all-cause mortality, 12 month ISHLT biopsy score (mean), along with the incidence of proven cytomegalovirus disease. In addition, the incidence of allograft vasculopathy as assessed by angiography or intravascular ultrasound was compared between groups.

Conditions

Interventions

TypeNameDescription
DRUGTacrolimustacrolimus
DRUGcombination therapyMMF

Timeline

Start date
2004-04-01
Primary completion
2009-06-01
Completion
2009-12-01
First posted
2006-03-06
Last updated
2015-05-28
Results posted
2015-05-28

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00299221. Inclusion in this directory is not an endorsement.